InVision Medical Technology

InVision Medical Technology has built arguably the strongest clinical evidence base of any AI vendor in echocardiography. Its two FDA-cleared products—Precision LVEF and Precision Cardiac Amyloid—are backed by publications in Nature, Nature Medicine, JAMA Cardiology, and NEJM AI, including the first blinded, randomized prospective trial of AI in cardiology. The cardiac amyloid algorithm was developed in collaboration with Alexion (AstraZeneca Rare Disease), holds FDA Breakthrough Device designation, and is enrolled in FDA's Total Product Lifecycle Advisory Program (TAP). A new CPT Category III code (0932T, effective Jan 1, 2025) provides a direct reimbursement path, turning the AI from a budget ask into a revenue-generating service. The platform integrates as post-processing on standard DICOM echo studies, requiring no new hardware or scanner changes, and works with existing PACS, Epic EHR, and structured reporting systems. The product pipeline is ambitious: Precision Cirrhosis (Breakthrough Device) for opportunistic liver disease detection from the subcostal echo view, and Precision Reporting powered by EchoPrime (a foundation model trained on over 12 million video-report pairs). Valve disease algorithms for mitral and tricuspid assessment have published in Circulation and JACC. Strengths: unmatched clinical validation, regulatory clearance, reimbursement pathway, enterprise integration, and a multi-indication platform that grows. Weaknesses: pricing is contact-only with no self-service or public tiers; integration requires existing PACS/Epic infrastructure (not for clinics without these); limited to post-processing (no real-time scanner integration); currently only two cleared algorithms; smaller private practices without enterprise procurement may find the process heavy. For health systems that already have the infrastructure and want regulatory-grade, peer-reviewed AI with a clear ROI and reimbursement pathway, InVision is a top-tier choice.